

Clinical cancer research
v. 19, no. 2 (Jan. 15 2013)
General Collection
W1 CL672
2013-01-29 10:41:50

Clinical Cancer Research

January 15, 2013 • Volume 19 • Number 2 • Pages 309–508



PROPERTY OF THE
NATIONAL
LIBRARY OF
MEDICINE

***The Journal of Clinical and
Translational Research***

Amgen Exhibit 1037
Amgen v. BMS



AACR's Esteemed Journal Collection

CANCER DISCOVERY

The essential information source to serve the diverse professional community in cancer science and medicine.

Cancer Research

Spanning the entire field, the most frequently cited cancer journal in the world.

Impact Factor: 7.856

Clinical Cancer Research

Clinical and translational research, bridging the laboratory and the clinic.

Impact Factor: 7.742

Cancer Epidemiology, Biomarkers & Prevention

Translating cancer science to populations.

Impact Factor: 4.123

Molecular Cancer Therapeutics

The Journal of Cancer Drug Discovery & Preclinical Development.

Impact Factor: 5.226

Molecular Cancer Research

Exploring the molecular and cellular biology of cancer.

Impact Factor: 4.288

Cancer Prevention Research

At the forefront of prevention science.

Impact Factor: 4.908

**COMING
SOON!**

Launching April 7, 2013

Cancer Immunology Research

January 2013 • Volume 1 • Number 1 • Pages 1-000

For Nonmember and Institutional Subscriptions:

U.S.A.: (860) 350-0041 or turpinna@turpin-distribution.com

International: (44) 1767-604951 or custserv@turpin-distribution.com

Japan: EBSCO: (81) 3 5327 5272 or japan@ebSCO.com

KINOKUNIYA Co., Ltd.: (81) 3 6910-0532 or journal@kinokuniya.co.jp

MARUZEN Co. Ltd.: (81) 3 3272 3878 or e-support@maruzen.co.jp

SWETS: (81) 3 3262 0701 or info@jpswets.com

USACO: (81) 3 3503 3256 or usaco@usaco.co.jp

Subscribe Today!

American Association for Cancer Research

615 Chestnut Street, 17th Floor • Philadelphia, PA 19106

For Site Licenses contact: pubsales@aacr.org

DF A999 P 9113
05/19/14 726 F1

Editor-in-Chief

Kenneth C. Anderson

Clinical Cancer Research

The Journal of Clinical and Translational Research

Deputy Editors

James L. Abbruzzese
Carlos L. Arteaga
William E. Barlow
Susan E. Bates
Jennifer R. Grandis
Eric H. Rubin
Patricia S. Steeg

Senior Editors

Ronald G. Blasberg
James H. Doroshow
Lee M. Ellis
Wael El-Rifai
Keith T. Flaherty
William E. Grizzle
Stephen M. Hahn
Thomas C. Hamilton
Roy S. Herbst
Marc Ladanyi
Jonathan Licht
Josep M. Llovet
Katherine K. Matthey
Ignacio J. Melero
Owen A. O'Connor
Kenneth Pienta
Jeremy N. Rich
Alex Sparreboom
Josep Tabernero
Beverly A. Teicher
Lawrence D. True
Theresa L. Whiteside

Editorial Board

Bharat B. Aggarwal
Joseph A. Aisner
Kenneth D. Aldape
Francis Ali-Osman
Carmen J. Allegra
David E. Avigan
Rebecca G. Bagley
Frank M. Balis
Robert C. Bast, Jr.
David G. Beer
James Berenson
Ray Bergan
Donald A. Berry
Joseph R. Bertino
Kapil N. Bhalla
Michael J. Birrer
Ernest C. Borden
Ruud H. Brakenhoff
Renier J. Brentjens
Ronald M. Bukowski
Barbara A. Burtness
Theresa Busch
Aman U. Buzdar
George A. Calin
Kevin Camphausen
Michael A. Carducci
William E. Carson
Paul B. Chapman
Dharminder Chauhan
Paul Chiao
Kathleen R. Cho
Fortunato Ciardiello
Gary M. Clark
Robert Clarke
Gary L. Clayman
Ezra E. W. Cohen
Michael B. Cohen
Barbara A. Conley
Jorge E. Cortes
William L. Dahut
Johann S. De Bono
Robert Diasio
Adam P. Dicker
Catherine Diefenbach
Federica

Di Nicolantonio
Colin P. Dinney
Robert DiPaola
Ethan Dmitrovsky
Glenn Dranoff
Ronny Drapkin
Louis Dubeau
Raymond N. DuBois
Elizabeth Eklund
Adel K. El-Naggar
Jeffrey Engelman
Alan L. Epstein
Francisco J. Esteva

Robert L. Ferris
Soldano Ferrone
William D. Figg
Richard S. Finn
Michelangelo Fiorentino
Antonio T. Fojo
David A. Frank
Arthur E. Frankel
Paul Frankel
Ralph S. Freedman
Gary E. Gallick
Varsha V. Gandhi
Stanton L. Gerson
Giuseppe Giaccone
Luca Gianni
Bonnie S. Glisson
Ajay Goel
Leo Gordon
Steven D. Gore
Andre H. Goy
James S. Goydos
Steven Grant
Tim F. Greden
Susan Groshen
Daniel F. Hayes
James G. Herman
Kenneth R. Hess
Teru Hideshima
Fred R. Hirsch
Walter N. Hittelman
Antje Hoering
Robert M. Hoffman
Gabriel N. Hortobagyi
Yujin Hoshida
Ralph Hruban
Patrick Hwu
Mark A. Israel
Jean-Pierre Issa
Rakesh K. Jain
Pasi Jänne
Jin Jen
John M. Jessup
Ricky W. Johnstone
Hagop Kantarjian
Gary Kao
Judith E. Karp
Scott H. Kaufmann
Stanley B. Kaye
Michael J. Kerin
Khandan Keyomarsi
Edward Kim
John M. Kirkwood
Elise C. Kohn
E. Anders Kolb
Scott Kopetz
Murray Korc

Jason A. Koutcher
Donald Kufe
Rakesh Kumar
Ho-Young Lee
Jin Soo Lee
Heinz-Josef D. Lenz
Ross L. Levine
Keith Ligon
Phillip O. Livingston
Patricia LoRusso
H. Kim Lyerly
Shuo Ma
Michael L. Maitland
Sami Malek
Sridhar Mani
David A. Mankoff
Li Mao
Maurie Markman
Andrew P. Mazar
David J. McConkey
Alan A. Melcher
Raymond E. Meyn
Frank Meyskens
Todd W. Miller
Randall E. Millikan
John D. Minna
Bruce D. Minsky
Constantine S. Mitsiades
Tetsuya Mitsudomi
Gareth J. Morgan
Michael A. Morse
Hasan Mukhtar
James L. Mulshine
Byung-Ho Nam
William G. Nelson
Steven J. O'Day
Shuji Ogino
Frank G. Ondrey
Ruth M. O'Regan
Robert Orlowski
Klaus Pantel
William Pao
Jae-Gahb Park
Harvey I. Pass
Ira Pastan
George Peoples
Roman Perez-Soler
Bill Plunkett
Yves Pommier
Pingping Qu
Jerry Radich
Ramesh K. Ramanathan
Mark J. Ratain
C. Patrick Reynolds
Antoni Ribas

Andrea Richardson
Paul M. Richardson
Victoria M. Richon
Michael J. Robertson
Rafael Rosell
Myrna R. Rosenfeld
Eric K. Rowinsky
Lawrence V. Rubinstein
David P. Ryan
John H. Sampson
Stefania Scala
Maurizio Scaltriti
Richard Schilsky
Gary K. Schwartz
Michael V. Seiden
Adrian M. Senderowicz
Violeta Serra
Dennis Sgroi
Jerry W. Shay
Dong M. Shin
Yu Shyr
Shivendra Singh
Susan F. Slovin
Keiran S.M. Smalley
David Solit
Vered Stearns
Cy A. Stein
Barry Storer
Walter J. Storkus
Yu-Tzu Tai
Chris H. Takimoto
Joel E. Tepper
Satoshi Teramukai
William D. Travis
Donald L. Trump
Jeffrey W. Tyner
David M. Vail
Martine Van Glabbeke
Carter Van Waes
Eduardo Vilar
Miguel A. Villalona-Calero
Augusto Villanueva
Everett E. Vokes
Robert H. Vonderheide
Jeffrey S. Weber
Wolfgang A. Weber
Robert Weil
Patrick Y. Wen
William H. Westra
Ignacio I. Wistuba
Keping Xie
Yun Yen
Benny Chung-Ying Zee

Editorial Office: *Clinical Cancer Research* [ISSN: 1078-0432 (Print); 1557-3265 (Online)] is published twice a month, one volume per year, by the American Association for Cancer Research, Inc. Periodicals postage paid at Philadelphia, PA, and additional mailing offices. POSTMASTER: Send address changes to *Clinical Cancer Research*, Member Services, AACR, 615 Chestnut Street, 17th Floor, Philadelphia, PA 19106-4404 or E-mail: membership@aacr.org. Copyright 2013 by the American Association for Cancer Research, Inc. Printed on acid free paper in the U.S.A.

Publishing Information

Clinical Cancer Research

The Journal of Clinical and Translational Research

Print ISSN: 1078-0432 • Online ISSN: 1557-3265

AACR Officers

Frank McCormick, President
Charles L. Sawyers, President-Elect
Judy E. Garber, Past President
William N. Hait, Treasurer
Margaret Foti, Chief Executive Officer

Publications Committee

Michael E. Berens
Gideon M. Bollag
Michael A. Caligiuri, Chairperson
Richard M. Caprioli
Arul M. Chinnaiyan
Joseph F. Costello
Chi Van Dang
Jessica Clague DeHart
Lisa Diller
Levi A. Garraway
John D. Groopman
Ernest T. Hawk
Sandra J. Horning
Nancy E. Hynes
Pasi A. Jänne
Emma M. Lees
Guillermina Lozano
Richard M. Marais
William G. Nelson
David R. Parkinson
David Piwnica-Worms
Robert H. Vonderheide

Publishing Staff

Publisher
Diane Scott-Lichter
Director, Editorial
Helen Barsky Atkins
Managing Editor
Lori Monteleone
Associate Editor
Jesse Potash
Features Editor
Brianna Gallagher
Editorial Staff
Kristin Dross
William J. Siegmann
Cara E. Vandy
Associate Director, Production
Charlene Squibb
Production Staff
David Livewell
Jeremy Rosenberg
Electronic Publishing Staff
Mary Beth Cunney
Diane M. Marinelli
Associate Director, Sales and Marketing
Nicola L. Hill
Assistant Director, Circulation and Fulfillment
Karola Rac

Marketing and Creative Services

Director
Paul Driscoll
Design Staff
Susan Moore

Scope

Clinical Cancer Research publishes innovative clinical and translational cancer research studies that bridge the laboratory and the clinic. The Journal is especially interested in clinical trials evaluating new treatments, accompanied by research on pharmacology and molecular alterations or biomarkers that predict response or resistance to treatment. The Journal also prioritizes laboratory and animal studies of new drugs and molecule-targeted agents with the potential to lead to clinical trials, and studies of targetable mechanisms of oncogenesis, progression of the malignant phenotype, and metastatic disease.

Clinical Cancer Research is abstracted and/or indexed in MEDLINE, Index Medicus, Web of Science, Science Citation Index, Current Contents/Clinical Medicine, Chemical Abstracts, and Scopus

Submission of Manuscripts

Online manuscript submission is welcomed at <http://ccr.msubmit.net>. Before submitting a manuscript, please read the Instructions for Authors, which is available from the Journal's home page at <http://clincancerres.aacrjournals.org>

Page Charges

Accepted manuscripts will be published with the understanding that the author(s) will pay a charge of \$95 per printed page for articles one to six pages in length; \$120 per additional page. Discounted charges are available for members.

Subscription Information

AACR Members. Subscription options are print with online access or online access only. Contact membership@aacr.org or see <http://www.aacr.org> and go to the membership page for further information.

Institutions. Send site license (includes remote and proxy server access) inquiries to pubsales@aacr.org or contact your local agent.

Nonmember Individuals. Subscriptions include print version with online access. Contacts listed below are for nonmember individual subscriptions.

USA, Canada, and Mexico
Turpin Distribution, The Bleachery, 143 West Street, New Milford, CT 06776; phone 860-350-0041, fax 860-350-0039, e-mail turpinna@turpin-distribution.com.

Japan
Send orders and inquiries to one of the following contacts: e-support@maruzen.co.jp; info@jp.swets.com; japan@ebSCO.com; journal@kinokuniya.co.jp; usaco@usaco.co.jp.

Rest of World (excluding above)
Turpin Distribution, Pegasus Drive, Stratton Business Park, Biggleswade, Bedfordshire SG18 8TQ, United Kingdom; phone +44-0-1767-604-957, fax +44-0-1767-604-957, fax +44-0-1767-601-640, e-mail custserv@turpin-distribution.com.

International subscriptions include cost of surface mail. Expedited mailing is available. Contact Turpin Distribution for rates.

Change of Address. Send change of address notification 60 days in advance and include both old and new addresses. Member subscribers should contact AACR Member Services, 615 Chestnut St., 17th Floor, Philadelphia, PA 19106-4404; e-mail

membership@aacr.org. Nonmember subscribers should contact Turpin Distribution, The Bleachery, 143 West Street, New Milford, CT 06776; e-mail turpinna@turpin-distribution.com, or Turpin Distribution, Pegasus Drive, Stratton Business Park, Biggleswade, Bedfordshire SG18 8TQ, United Kingdom; e-mail custserv@turpin-distribution.com.

Claims. Claims for missing issues made within 90 days of the issues publication date will be honored while supplies last. Member subscribers should contact membership@aacr.org, phone 215-440-9300, fax 215-440-9412. Institutions and nonmember subscribers should direct claims to Turpin Distribution at the appropriate address above or by e-mail turpinna@turpin-distribution.com.

Single Issue Sales. Single issues and back stock of the journals may be ordered from the AACR main office by calling 866-423-3965 (toll-free) or 215-440-9300. Price of a single issue is \$60 and includes U.S. surface postage. Orders outside of the U.S. are \$65 and include postage.

Advertising Information

Inquiries about advertising should be directed to: Pharmaceutical Media Inc., 30 East 33rd St., 4th Floor, NY, NY, 10016; Phone: 212-685-5010; e-mail: Gbennicasa@pmi.com

Copyright and Permissions

As a not-for-profit organization incorporated in the United States, AACR adheres to U.S. copyright law (PL 94-553), which became effective January 1, 1978. The law stipulates that copyright for works is vested in the author from the moment of creation and remains the property of the author until legally transferred. Authors who wish to publish articles and other material in AACR journals must formally transfer copyright to AACR. The copyright transfer form must be signed by all authors before AACR can proceed with publication.

After a manuscript has been deemed potentially acceptable, all authors on the manuscript will be requested to complete an online copyright transfer agreement through the SmartSubmit system. The AACR journals will not publish a paper unless forms have been properly completed and returned by ALL authors.

To read the complete version of AACR's Copyright and Permissions Policy, please visit <http://clincancerres.aacrjournals.org/site/misc/permissions.xhtml>. This policy includes further information on authors' rights of usage, permission requests from third parties, free access to AACR journals, funding agency requirements, and the National Institutes of Health Public Access Policy.

No responsibility is accepted by the Editors or by AACR, Inc. for the opinions expressed by contributors or for the content of the advertisements.

American Association for Cancer Research
615 Chestnut Street
Philadelphia, PA 19106-4404
Phone: 215-440-9300
Fax: 215-440-9354
E-mail: ccr@aacr.org
Website: www.aacr.org

Highlights of This Issue 309

SPECIAL FEATURES

CCR Translations

- 311 | **Targeted Isotretinoin in Neuroblastoma: Kinetics, Genetics, or Absorption**
Katherine K. Matthay
See article, p. 469

Statistics in Clinical Cancer Research

- 314 | **Tumor Burden Modeling Versus Progression-Free Survival for Phase II Decision Making**
Lee D. Kaiser

Molecular Pathways

- 320 | **Molecular Pathways: Comparing the Effects of Drugs and T Cells to Effectively Target Oncogenes**
Kathleen Anders and Thomas Blankenstein

Review

- 327 | **The Role of JAK Pathway Dysregulation in the Pathogenesis and Treatment of Acute Myeloid Leukemia**
Hun Ju Lee, Naval Daver, Hagop M. Kantarjian, Srdan Verstovsek, and Farhad Ravandi

HUMAN CANCER BIOLOGY

- 336 | **Tumoral Lymphocytic Infiltration and Expression of the Chemokine CXCL10 in Breast Cancers from the Ontario Familial Breast Cancer Registry**
Anna Marie Mulligan, Irene Raitman, Linda Feeley, Dushanthi Pinnaduwage, Linh T. Nguyen, Frances P. O'Malley, Pamela S. Ohashi, and Irene L. Andrulis

CANCER THERAPY: PRECLINICAL

- 347 | **Milatuzumab-Conjugated Liposomes as Targeted Dexamethasone Carriers for Therapeutic Delivery in CD74⁺ B-cell Malignancies**
Yicheng Mao, Georgia Triantafyllou, Erin Hertlein, William Towns, Matthew Stefanovski, Xiaokui Mo, David Jarjoura, Mitch Phelps, Guido Marcucci, Ly James Lee, David M. Goldenberg, Robert J. Lee, John C. Byrd, and Natarajan Muthusamy
- 357 | **BMS-936564/MDX-1338: A Fully Human Anti-CXCR4 Antibody Induces Apoptosis *In Vitro* and Shows Antitumor Activity *In Vivo* in Hematologic Malignancies**
Michelle R. Kuhne, Tanya Mulvey, Blake Belanger, Sharline Chen, Chin Pan, Colin Chong, Fei Cao, Wafa Niekro, Tom Kempe, Karla A. Henning, Lewis J. Cohen, Alan J. Korman, and Pina M. Cardarelli
- 367 | ***In Vitro* Sensitivity of CLL Cells to Fludarabine May Be Modulated by the Stimulation of Toll-like Receptors**
Eleonora Fonte, Benedetta Apollonio, Lydia Scarfò, Pamela Ranghetti, Claudia Fazi, Paolo Ghia, Federico Caligaris-Cappio, and Marta Muzio
- 380 | **c-Src Activation Mediates Erlotinib Resistance in Head and Neck Cancer by Stimulating c-Met**
Laura P. Stabile, Guoqing He, Vivian Wai Yan Lui, Cassandra Henry, Christopher T. Gubish, Sonali Joyce, Kelly M. Quesnelle, Jill M. Siegfried, and Jennifer R. Grandis
- 393 | **BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice**
Chengwen Liu, Weiye Peng, Chunyu Xu, Yanyan Lou, Minying Zhang, Jennifer A. Wargo, Jie Qing Chen, Haiyan S. Li, Stephanie S. Watowich, Yan Yang, Dennie Tompers Frederick, Zachary A. Cooper, Rina M. Mbofung, Mayra Whittington, Keith T. Flaherty, Scott E. Woodman, Michael A. Davies, Laszlo G. Radvanyi, Willem W. Overwijk, Gregory Lizée, and Patrick Hwu

- 404 **PLK1 Inhibitors Synergistically Potentiate HDAC Inhibitor Lethality in Imatinib Mesylate-Sensitive or -Resistant BCR/ABL⁺ Leukemia Cells *In Vitro* and *In Vivo***
Girija Dasmahapatra, Hiral Patel, Tri Nguyen, Elisa Attkisson, and Steven Grant
- 415 **Complete Regression of Metastatic Renal Cell Carcinoma by Multiple Injections of Engineered Mesenchymal Stem Cells Expressing Dodecameric TRAIL and HSV-TK**
Sae Won Kim, Su Jin Kim, Sang Hoon Park, Hyun Gul Yang, Moon Cheol Kang, Young Woo Choi, Seong Muk Kim, Sin-Soo Jeun, and Young Chul Sung
- 428 **Dysregulation of the Repressive H3K27 Trimethylation Mark in Head and Neck Squamous Cell Carcinoma Contributes to Dysregulated Squamous Differentiation**
Orla M. Gannon, Lilia Merida de Long, Liliana Endo-Munoz, Mehlika Hazar-Rethinam, and Nicholas A. Saunders

IMAGING, DIAGNOSIS, PROGNOSIS

- 442 **Variation in Precursor Lesions of Pancreatic Cancer among High-Risk Groups**
Thomas P. Potjer, Ingrid Schot, Peter Langer, Johannes T. Heverhagen, Martin N.J.M. Wasser, Emily P. Slater, Günter Klöppel, Hans M. Morreau, Bert A. Bosing, Wouter H. de Vos tot Nederveen Cappel, Mathias Bargello, Thomas M. Gress, Hans F.A. Vasen, and Detlef K. Bartsch on behalf of the Leiden Familial Pancreatic Cancer Group and the FaPaCa registry
- 450 **Prognostic Significance of AKT/mTOR and MAPK Pathways and Antitumor Effect of mTOR Inhibitor in NF1-Related and Sporadic Malignant Peripheral Nerve Sheath Tumors**
Makoto Endo, Hidetaka Yamamoto, Nokitaka Setsu, Kenichi Kohashi, Yusuke Takahashi, Takeaki Ishii, Kei-ichiro Iida, Yoshihiro Matsumoto, Michiyuki Hakozaki, Mikiko Aoki, Hiroshi Iwasaki, Yoh Dobashi, Kenichi Nishiyama, Yukihide Iwamoto, and Yoshinao Oda

CANCER THERAPY: CLINICAL

- 462 **Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody**
Evan J. Lipson, William H. Sharfman, Charles G. Drake, Ira Wollner, Janis M. Taube, Robert A. Anders, Haiying Xu, Sheng Yao, Alice Pons, Lieping Chen, Drew M. Pardoll, Julie R. Brahmer, and Suzanne L. Topalian
- 469 **Adaptive Dosing Approaches to the Individualization of 13-*Cis*-Retinoic Acid (Isotretinoin) Treatment for Children with High-Risk Neuroblastoma**
Gareth J. Veal, Julie Errington, Sophie E. Rowbotham, Nicola A. Illingworth, Ghada Malik, Michael Cole, Ann K. Daly, Andrew D.J. Pearson, and Alan V. Boddy
See commentary, p. 311

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE


- 480 **Detection of Novel Actionable Genetic Changes in Salivary Duct Carcinoma Helps Direct Patient Treatment**
Valentina Nardi, Peter M. Sadow, Dejan Juric, Dave Zhao, Arjola K. Cosper, Kristin Bergethon, Vanessa L. Scialabba, Julie M. Batten, Darrell R. Borger, Anthony John Iafrate, Rebecca S. Heist, Donald P. Lawrence, Keith T. Flaherty, Johanna C. Bendell, Daniel Deschler, Yi Li, Lori J. Wirth, and Dora Dias-Santagata
- 491 **Integration of Cell Line and Clinical Trial Genome-Wide Analyses Supports a Polygenic Architecture of Paclitaxel-Induced Sensory Peripheral Neuropathy**
Heather E. Wheeler, Eric R. Gamazon, Claudia Wing, Uchenna O. Njiaju, Chidiamara Njoku, Robert Michael Baldwin, Kouros Owzar, Chen Jiang, Dorothy Watson, Ivo Shterev, Michiaki Kubo, Hitoshi Zembutsu, Eric P. Winer, Clifford A. Hudis, Lawrence N. Shulman, Yusuke Nakamura, Mark J. Ratain, and Deanna L. Kroetz for the Cancer and Leukemia Group B; Nancy J. Cox, and Mary Eileen Dolan

CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSCG) 8

Matthew P. Goetz, Vera J. Suman, Tanya L. Hoskin, Michael Gnant, Martin Filipits, Stephanie L. Safgren, Mary Kuffel, Raimund Jakesz, Margaretha Rudas, Richard Greil, Otto Dietze, Alois Lang, Felix Offner, Carol A. Reynolds, Richard M. Weinshilboum, Matthew M. Ames, and James N. Ingle

RETRACTION**Retraction: Evaluation of Colon Cancer-Specific Antigen 2 as a Potential Serum Marker for Colorectal Cancer****ABOUT THE COVER**


Confocal immunofluorescent image showing the effects of the polycomb repressor complex 2 inhibitor 3-deazaneplanocin A on tumor cellularity and apoptosis in a xenotransplant model of human head and neck cancer. Immunodeficient mice were injected with a head and neck cancer cell line which was allowed to establish prior to daily treatment with 5 mg/kg DZNep. Tumor tissue has been stained with DAPI to highlight cell nuclei. Green immunofluorescence highlights the human epithelial tumor cells (AEI/III positive) and red fluorescence highlights caspase III positive dying cells. For details, see the article by Gannon and colleagues on page 428 of this issue.



SCIENTIFIC CONFERENCES 2013:

Presenting the most significant research on cancer etiology,
prevention, diagnosis, and treatment

www.aacr.org/Conferences2013



Tumor Invasion and Metastasis

Co-Chairpersons: Zena Werb and Bruce R. Zetter
January 20-23, 2013 • San Diego, CA

Ninth AACR-Japanese Cancer Association Joint Conference: Breakthroughs in Basic and Translational Cancer Research

Co-Chairpersons: Tyler Jacks and Kohei Miyazono
February 21-25, 2013 • Maui, HI

Joint AACR-Society of Nuclear Medicine and Molecular Imaging Conference: State-of-the-Art Molecular Imaging in Cancer Biology and Therapy

Co-Chairpersons: Carolyn J. Anderson and David Piwnica-Worms
February 27-March 2, 2013 • San Diego, CA

AACR Annual Meeting 2013

Chairperson: José Baselga
April 6-10, 2013 • Washington, DC

Synthetic Lethal Approaches to Cancer Vulnerabilities

Co-Chairpersons: William C. Hahn, Sebastian Nijman, and Louis M. Staudt
May 17-20, 2013 • Bellevue, WA

Chromatin and Epigenetics in Cancer

Co-Chairpersons: Suzanne J. Baker, Charles W.M. Roberts, and Gerald R. Crabtree
June 19-22, 2013 • Atlanta, GA

Frontiers in Basic Cancer Research

Chairperson: Scott W. Lowe
Co-Chairpersons: Joan S. Brugge, Hans Clevers, Carol L. Prives, and Davide Ruggero
September 18-22, 2013 • National Harbor, MD

Advances in Ovarian Cancer Research: From Concept to Clinic

Co-Chairpersons: David G. Huntsman, Douglas A. Levine, and Sandra Orsulic
September 18-21, 2013 • Miami, FL

Advances in Breast Cancer Research

Co-Chairpersons: Carlos L. Arteaga, Jeffrey M. Rosen, Jane E. Visvader, and Douglas Yee
October 3-6, 2013 • San Diego, CA

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Co-Chairpersons: Jeffrey A. Engelman, James H. Doroshow, and Sabine Tejpar
October 19-23, 2013 • Boston, MA

Twelfth Annual International Conference on Frontiers in Cancer Prevention Research

Chairperson: Paul J. Limburg
October 27-30, 2013 • National Harbor, MD

Pediatric Cancer at the Crossroads:

Translating Discovery into Improved Outcomes
Co-Chairpersons: John M. Maris, Stella M. Davies, James R. Downing, Lee J. Helman, and Michael B. Kastan
November 3-6, 2013 • San Diego, CA

The Translational Impact of Model Organisms in Cancer

Co-Chairpersons: Cory Abate-Shen, A. Thomas Look, and Terry A. Van Dyke
November 5-8, 2013 • San Diego, CA

CTRC-AACR San Antonio Breast Cancer Symposium

Co-Directors: Carlos L. Arteaga, C. Kent Osborne, and Peter M. Ravdin
December 10-14, 2013 • San Antonio, TX

AACR EDUCATIONAL WORKSHOPS

Accelerating Anticancer Agent Development and Validation

Co-Chairpersons: H. Kim Lyerly and Richard Pazdur
May 8-10, 2013
Bethesda, MD

NEW! Integrative Molecular Cancer Epidemiology

Director: Thomas A. Sellers;
Co-Directors: Peter L. Kraft and Margaret R. Spitz
July 15-20, 2013
Boston, MA

Molecular Biology in Clinical Oncology

Co-Directors: William G. Kaelin Jr., Mark Geraci, and Suzanne Topalian
July 21-28, 2013
Snowmass, CO

ASCO/AACR Methods in Clinical Cancer Research

Co-Directors: Jamie H. von Roenn, Neal J. Meropol, and Mithat Gönen
July 27-August 2, 2013
Vail, CO

Translational Research for Basic Scientists

Co-Directors: Tom Curran, George D. Demetri, and Pasi A. Jänne
Fall 2013
Boston, MA

www.aacr.org/Workshops2013

Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody

Evan J. Lipson¹, William H. Sharfman^{1,3}, Charles G. Drake^{1,2}, Ira Wollner⁶, Janis M. Taube^{3,4}, Robert A. Anders⁴, Haiying Xu⁴, Sheng Yao^{1,3}, Alice Pons¹, Lieping Chen^{1,3}, Drew M. Pardoll¹, Julie R. Brahmer¹, and Suzanne L. Topalian⁵

Abstract

Purpose: Results from the first-in-human phase I trial of the anti-programmed death-1 (PD-1) antibody BMS-936558 in patients with treatment-refractory solid tumors, including safety, tolerability, pharmacodynamics, and immunologic correlates, have been previously reported. Here, we provide long-term follow-up on three patients from that trial who sustained objective tumor regressions off therapy, and test the hypothesis that reinduction therapy for late tumor recurrence can be effective.

Experimental Design: Three patients with colorectal cancer, renal cell cancer, and melanoma achieved objective responses on an intermittent dosing regimen of BMS-936558. Following cessation of therapy, patients were followed for more than 3 years. A patient with melanoma who experienced a prolonged partial regression followed by tumor recurrence received reinduction therapy.

Results: A patient with colorectal cancer experienced a complete response, which is ongoing after 3 years. A patient with renal cell cancer experienced a partial response lasting 3 years off therapy, which converted to a complete response, which is ongoing at 12 months. A patient with melanoma achieved a partial response that was stable for 16 months off therapy; recurrent disease was successfully treated with reinduction anti-PD-1 therapy.

Conclusion: These data represent the most prolonged observation to date of patients with solid tumors responding to anti-PD-1 immunotherapy and the first report of successful reinduction therapy following delayed tumor progression. They underscore the potential for immune checkpoint blockade with anti-PD-1 to reset the equilibrium between tumor and the host immune system. *Clin Cancer Res*; 19(2); 462–8. ©2012 AACR.

Introduction

The specific or selective expression of antigens by cancer cells creates an opportunity for endogenous cell-mediated and serologic immune attack and for immunotherapeutic interventions. The development of effective cancer immunotherapies depends on reversing inhibitory and tolerogenic signals in the tumor microenvironment, thereby enhancing the visibility of tumor cells to the immune system. In the last decade, it has become clear that the

immune regulatory pathway composed of programmed death-1 (PD-1, CD279), a receptor expressed on activated T and B cells and its ligands PD-L1 (B7-H1, CD274) and PD-L2 (B7-DC, CD273), plays an integral role in the down-modulation of antitumor immunity. Inhibition of this pathway using blocking monoclonal antibodies (mAb) against PD-1 or PD-L1 is emerging as an effective method for reversing cancer immunosuppression and thereby causing tumor regression in patients with advanced disease (1). Although such therapies are still in development, they have shown promising clinical results not only for tumors classically considered to be immunogenic such as melanoma and renal cell carcinoma (RCC), but also for common epithelial malignancies such as non-small cell lung cancer (NSCLC), historically resistant to immunotherapy.

BMS-936558 (MDX-1106/ONO-4538) is a blocking mAb specific for human PD-1. The first-in-human single-dose, dose-escalation trial of this agent reported by Brahmer and colleagues (2) enrolled 39 patients with treatment-refractory metastatic solid tumors including melanoma, RCC, colorectal cancer (CRC), NSCLC, and castration-resistant prostate cancer (CRPC). A favorable safety profile and preliminary evidence of clinical activity in all histologies except CRPC led to the design of a multidose trial of

Authors' Affiliations: Departments of ¹Oncology, ²Urology, ³Dermatology, ⁴Pathology, and ⁵Surgery, Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland; and ⁶Department of Internal Medicine, Wayne State University School of Medicine and Henry Ford Hospital, Detroit, Michigan

Current address for S. Yao and L. Chen: Department of Immunobiology, Yale University, New Haven, CT 06519.

Corresponding Author: Evan J. Lipson, Department of Oncology, Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, 1550 Orleans Street, David H. Koch Cancer Research Building, Baltimore, MD 21287. Phone: 410-502-8200; Fax: 410-502-1958; E-mail: evanlipson@jhmi.edu; and Suzanne L. Topalian. E-mail: stopali1@jhmi.edu

doi: 10.1158/1078-0432.CCR-12-2625

©2012 American Association for Cancer Research.

Translational Relevance

This report provides long-term follow-up on patients from the first-in-human trial of the anti-PD-1 antibody BMS-936558 (MDX-1106) who achieved objective tumor regressions. They include patients with metastatic melanoma, colorectal, and renal cancer. Remarkably, durable responses including continued tumor regression off therapy were observed. Furthermore, a patient with melanoma, who experienced tumor recurrence following a prolonged partial response, responded to reinduction with anti-PD-1 therapy. These findings of durable treatment effect underscore the potential for immune-based therapies such as antibodies blocking the immunosuppressive PD-1/PD-L1 pathway to reset the equilibrium between tumor and the host immune system, distinguishing them from conventional chemotherapies as well as small-molecule inhibitors of oncogenic driver pathways. They represent the most prolonged observation of patients with solid tumors responding to anti-PD-1 immunotherapy to date, and the first evidence that reinduction therapy with this agent after late tumor recurrence may be effective.

BMS-936558 in 296 patients that was recently reported (3), confirming antitumor efficacy in melanoma, RCC, and NSCLC.

The adaptive immune system has a vast capacity for specific antigen recognition and holds the potential to adjust to ongoing tumor evolution, including genetic and epigenetic changes that typically cause resistance to small-molecule inhibitors. This adaptability, coupled with an immune memory component, implies that immunotherapy can "reorient" endogenous antitumor immunity with durable effects even after the cessation of therapy. Here, we provide long-term follow-up on patients from the first-in-human trial of BMS-936558 who achieved objective tumor regressions, including a patient with CRC who maintained a complete response (CR) off therapy; a patient with RCC who sustained a partial response (PR) that converted to a CR off therapy; and a patient with melanoma who experienced a prolonged PR off therapy followed by tumor progression and then response to reinduction therapy with the same anti-PD-1 antibody. These data represent the most prolonged observation of patients with solid tumors responding to anti-PD-1 therapy and the first evidence that reinduction therapy with this agent after late tumor progression may be effective. The observed durability of responses underscores the potential for immune checkpoint blockade with anti-PD-1 to reset the equilibrium between tumor and host and provide durable tumor control after cessation of therapy.

Materials and Methods

Treatments administered and response evaluation

BMS-936558, a fully human immunoglobulin G4 (IgG4) blocking mAb against PD-1, was administered in a multi-

institutional, first-in-human, phase I dose-escalation study (2). The protocol was approved by local Institutional Review Boards (IRB), and all participating subjects signed informed consent. The antibody was given as a single intravenous infusion at 0.3 to 10 mg/kg per dose, followed by radiologic restaging at 8 and 12 weeks. Responses were evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) 1.0. Patients who tolerated the drug well (no adverse events $\geq$ grade 3 and no development of human antihuman antibodies) and showed stable disease or any evidence of tumor regression were eligible for retreatment at weeks 12 and 16. Patients who achieved an objective response (PR or CR) discontinued dosing and were observed with periodic radiologic restaging.

A patient with melanoma who experienced a prolonged PR followed by tumor progression received reinduction therapy with BMS-936558 10 mg/kg on days 1, 29, and 86, repeated every 120 days, on a single patient use clinical trial following IRB approval and informed consent. In contrast to the original dosing schema, treatment on this trial may continue until the patient develops a confirmed CR, confirmed progressive disease, or unacceptable toxicity.

Tumor biopsies and immunohistochemistry

Histologic slides were reviewed to confirm the cancer diagnosis, and one representative formalin fixed, paraffin embedded (FFPE) block of tumor was chosen for immunohistochemical (IHC) analysis to characterize the tumor and its microenvironment. PD-L1 immunostaining was conducted with the mAb 5H1 as previously described (4). The method for PD-1 immunostaining parallels that reported for PD-L1 with minor modifications. The murine antihuman PD-1 mAb, clone M3, was used at a concentration of 1.0 μ g/mL. Citrate buffer (pH 6.0) was used for antigen retrieval, and a CSA System (DAKO) was used for signal amplification, followed by development with diaminobenzidine chromagen that results in brown staining. In the heavily pigmented melanoma, a Giemsa counterstain was used for the PD-1 antibody. This results in green coloration of the melanin pigment and facilitates interpretation of the brown signal (5). CD3, CD4, CD8, CD68, and T-cell intracytoplasmic antigen-1 (TIA-1) immunostains were conducted according to routine automated methods.

Results

Among 39 patients with treatment-refractory solid tumors receiving BMS-936558 on an intermittent dosing regimen (2), 3 objective tumor regressions were observed. Following are the clinical and immunologic assessments of these patients during prolonged observation.

Durable complete response in colorectal cancer

A 71-year-old male with CRC underwent a right hemicolectomy in October 2003, revealing a moderately differentiated adenocarcinoma with metastases to 4 of 16 pericolic lymph nodes and vascular and perineural invasion [G₂, pT3N2; microsatellite instability (MSI)-high genotype]. He received adjuvant 5-fluorouracil (5-FU) and

leucovorin; however, a CT scan the following year revealed metastatic disease. Over the subsequent 3 years, the patient received multiple chemotherapeutic regimens with temporary response but then progression at multiple lymph node sites (gastrohepatic, portacaval, and peripancreatic); therapies included FOLFOX, irinotecan, bevacizumab, and cetuximab. Chemotherapy was last administered in April 2007. The patient began therapy with anti-PD-1 at 3 mg/kg per dose in July 2007 after documentation of disease progression, and received 5 doses over the next 9 months. CT scans conducted 8 and 12 weeks after a single dose of anti-PD-1 showed a partial response (Fig. 1A). A CR was achieved in January 2008, and periodic CT and PET scans have revealed no evidence of recurrence since then. The patient was most recently evaluated in April 2011, at which time he had not received any antineoplastic therapy for 3 years and had no evidence of disease recurrence.

IHC studies of the primary colon tumor, conducted on FFPE tissues archived 4 years before the initiation of anti-PD-1 therapy, revealed cell surface ("membranous") expression of PD-L1 by infiltrating macrophages and lymphocytes and by rare tumor cells, associated with infiltrating PD-1+ and CD3+ T cells (Fig. 1B). We have previously reported

preliminary evidence for a correlation between tumor cell membranous PD-L1 expression and the likelihood of response to anti-PD-1 therapy (2). Potential relationships between PD-L1 expression on nontumor cells and clinical outcomes require further study (4).

Evolution of complete tumor regression off therapy in renal cell carcinoma

A 76-year-old male underwent a right nephrectomy and vena caval thrombectomy in 2001, showing clear cell renal carcinoma. He developed bilateral pulmonary metastases in 2003 and received systemic therapies including the histone deacetylase inhibitor mocetinostat, sorafenib, and sunitinib, experiencing disease progression with new metastatic sites in mediastinal lymph nodes, bone, and paraspinal musculature. In January 2008, he began treatment with anti-PD-1 at 10 mg/kg per dose. CT scans conducted in March 2008, 8 weeks after a single dose of anti-PD-1, showed a mixed response: pulmonary, lymph node, and intramuscular metastases were regressing, but lesions were enlarging in the pancreas and bone. The patient also developed hypothyroidism, which was assessed as possibly treatment related. He received 2 more doses of anti-PD-1 in April





Figure 1. Response of metastatic colorectal cancer to anti-PD-1 therapy. A, computed tomographic scan showing partial regression of a representative lymph node metastasis in a patient with CRC, after receiving a single dose of anti-PD-1. B, hematoxylin and eosin (H&E) staining and IHC analysis of primary colon tumor from this patient, showing PD-L1+ lymphohistiocytic infiltrates surrounding tumor cells, and rare PD-L1+ tumor cells, interposed with CD3+ and PD-1+ infiltrating T cells. Arrow denotes tumor cells. Original magnification, $\times 200$.

and May 2008; a CT scan in July 2008 showed a PR compared with baseline tumor measurements, including disappearance of the pancreatic lesion (Fig. 2A); the bone metastasis slowly resolved (2). PR status was maintained off therapy until February 2009, when a restaging brain CT and

subsequent brain MRI showed a new enhancing 1.4-cm lesion in the inferior right frontal lobe, with intralesional hemorrhage and surrounding edema, consistent with metastasis (Fig. 2B). Resection of this asymptomatic mass revealed fibrovascular tissue with macrophages and chronic

Figure 2. Regression of metastatic RCC following anti-PD-1 therapy, with "immune-related" response characteristics. **A**, contrast-enhanced CT scans showing regression of a biopsy-proven paraspinal intramuscular metastasis (top row, arrows) and concomitant progression followed by regression of a pancreatic lesion (bottom row, arrows) in a patient who received 3 doses of anti-PD-1. **B**, newly appearing lesion radiologically compatible with brain metastasis, as shown on T1-weighted contrast-enhanced magnetic resonance imaging, with intralesional hemorrhage and surrounding edema (left). Pathologic evaluation of the resected lesion on H&E staining revealed fibrosis (asterisk), a chronic inflammatory cell infiltrate, and old hemorrhage consistent with a resolving process. There was no morphologic or immunohistochemical evidence of RCC (no expression of PAX-8, EMA, or AE1/AE3; data not shown). Immunostaining to characterize the inflammatory infiltrate shows a lymphocytic infiltrate with CD8 predominance when compared with CD4. The CD8 cells were also TIA-1 positive, supporting a cytotoxic phenotype (not shown). Staining for CD68 highlighted numerous hemosiderin-laden macrophages in the inflammatory infiltrate. Original magnification, $\times 200$. **C**, continued regression of multiple metastatic sites over time, following cessation of anti-PD-1 therapy. Drug administration is indicated by arrows. The lesion marked with an asterisk became calcified on CT scan and showed no FDG activity on PET scan. LN, lymph node; IM, intramuscular.



inflammation but no evidence of tumor; this was consistent with a resolving lesion of undetermined origin. No further antineoplastic therapy was administered and metastatic lesions continued to regress off therapy (Fig. 2C). A CR was documented with CT and PET scans in August 2011. This patient remains in remission as of radiologic evaluation in August 2012, more than 4 years after discontinuation of anti-PD-1 therapy.

Reinduction therapy for recurrent melanoma

A 55-year-old female was diagnosed with metastatic melanoma following biopsy of a left axillary mass in 2006; the primary site of origin was undetermined. Further workup revealed liver metastases. Disease progression occurred despite therapy with high-dose interleukin-2 and temozolomide. Eight weeks after receiving one dose of anti-

PD-1 at 10 mg/kg in October 2007, CT scans revealed a mixed picture: lesions in the liver and left axilla were stable or regressing, whereas a left subpectoral lymph node had enlarged (Fig. 3A). Two more doses of anti-PD-1 were administered in January and February 2008. CT scans conducted in April and May 2008 again showed a mixed response with interval development of central necrosis in some lesions. The patient continued to receive anti-PD-1 therapy through June 2009, and a PR compared with baseline measurements was documented in August 2009. Per protocol, treatment was discontinued. A stable PR persisted until December 2010, when a restaging PET/CT scan revealed newly enlarged, FDG-avid precarinal and subcarinal lymph nodes. A transbronchial biopsy of the subcarinal lesion confirmed a diagnosis of melanoma (Fig. 3B). Similar to prior IHC studies of an axillary lymph




Figure 3. Response of metastatic melanoma to reinduction anti-PD-1 therapy. **A**, initial partial regression of liver and lymph node (LN) metastases in a melanoma patient treated with anti-PD-1. Drug administration is indicated by arrows. Recurrent disease in mediastinal lymph nodes while off therapy was successfully treated with reinduction therapy. The lesion marked with an asterisk developed peripheral calcification and showed minimal PET activity. **B**, membranous (cell surface) PD-L1 expression by metastatic melanoma cells in a transbronchial biopsy of a subcarinal lymph node mass, before reinduction therapy. Tumor infiltration by CD8+ and PD-1+ T cells is evident (arrows). Original magnification, $\times 200$. **C**, PET scans before first treatment with anti-PD-1 (August 2007), before reinduction therapy (December 2010), and following reinduction (November 2011). Resolution of a left axillary lymph node metastasis that was present before anti-PD-1 therapy, and response of a new subcarinal lymph node metastasis to reinduction therapy, are shown (arrows). **D**, regression of new mediastinal lymph node metastasis following reinduction therapy with anti-PD-1, shown in contrast-enhanced CT scans.

node metastasis in this patient (2), there was intense membranous tumor cell expression of PD-L1 and infiltration by CD8+ and PD-1+ T cells. A patient-specific protocol providing for reinduction therapy with BMS-936558 was approved by the Johns Hopkins IRB (Baltimore, MD), and treatment was reinitiated in May 2011. After the patient received 2 doses of anti-PD-1, a PET/CT scan in November 2011 showed near complete resolution of the abnormal metabolic activity in the subcarinal lymph node and no new lesions (Fig. 3C). CT scan showed a 40% tumor regression of the new mediastinal adenopathy compared with reinduction baseline measurements (Fig. 3D). The patient continues on anti-PD-1 at the time of this report, with a sustained PR documented 16 months following initiation of reinduction therapy.

Discussion

The successful application of PD-1/PD-L1 pathway blockade in treating a diversity of solid tumors underscores the power of immunotherapy in combating not only cancers traditionally considered to be immunogenic, such as melanoma and RCC, but also epithelial malignancies such as NSCLC and CRC which are commonly viewed as refractory to immunotherapy. The activity of agents blocking this pathway is currently being explored in multiple new indications in oncology, including ovarian, breast, gastric, and pancreatic cancer. Preclinical evidence suggests that continuous antigen exposure of cytolytic T cells may induce a tolerant or "exhausted" state in which T-cell effector functions and transition to memory T cells are impaired. PD-1 pathway blockade may restore the functions of exhausted T cells with long-term clinical benefit generating powerful memory T cells that may provide an ongoing antitumor dynamic and keep tumors in check for months to years, even in the absence of continued therapy (6). This hypothesis is consistent with the results of the current study and is highlighted by the RCC case, in which partially responsive metastatic deposits continued to regress off therapy and eventuated in a durable CR. The new brain lesion resected from this patient in the interim, while not independently diagnostic, was consistent with a healing lesion such as might occur at a site of tumor regression. Similar pathologic features, including tumor necrosis in the presence of complex immune cell infiltrates, have been described in post-treatment tumor biopsies from patients receiving anti-CTLA-4 immunotherapy (7). These findings suggest the potential of PD-1 pathway blockade to reset the immune equilibrium between tumor and host (8). It follows that tumor recurrence after a response may reflect a disturbance in this equilibrium, as illustrated by the melanoma patient described herein. Repeat application of PD-1 blockade in this patient, whose recurrent tumor strongly expressed PD-L1 and contained PD-1+ infiltrating lymphocytes, reinduced a rapid partial tumor regression. Unlike tumors exposed to tyrosine kinase inhibitors that may rapidly acquire resistance and exhibit progression during continued drug exposure, due to the emergence of new genetic or epigenetic alterations (9), tumor progression in this patient

occurred only after therapy was discontinued. These findings suggest a potential role for continued administration of anti-PD-1 on an intermittent "maintenance" schedule after achieving an objective tumor regression to preserve an immune equilibrium and protect the host from tumor regrowth.

The findings described herein also show the importance of establishing new immune-related RECIST (iRECIST) criteria to evaluate patients undergoing therapy with agents blocking immune checkpoints such as anti-PD-1. These agents are not directly tumoricidal but work indirectly by activating antitumor immunity and thus may be associated with delayed response kinetics (10). As exemplified by the patients with melanoma and RCC reported here, metastatic lesions may appear anew or enlarge before showing evidence of regression (11). "Mixed" responses characterized by the simultaneous growth of some lesions and regression of others have also been observed. These unconventional response patterns may provide survival benefits, which remain to be determined in future randomized trials of PD-1 blockade. Indeed, these principles are illustrated by randomized trials of immune checkpoint blockade with ipilimumab (anti-CTLA-4) in patients with advanced melanoma, where overall survival rates exceeded objective response rates (CR+PR; refs. 12, 13), suggesting the possibility of a new paradigm for evaluating clinical benefit that does not rely solely on traditional RECIST response criteria. Development of iRECIST criteria in combination with biomarkers that reliably predict clinical response will be vital as an increasing number of immunotherapies become commercially available (14).

Since the publication of the first-in-human phase I trial of BMS-936558 using an intermittent dosing regimen (2), this drug has been tested in a follow-up phase I trial with cohort expansion, using biweekly administration to patients with various treatment-refractory solid malignancies (3). Objective responses (PR or CR) were observed in 18% of patients with NSCLC, 28% with melanoma, and 27% with RCC. Grade 3 to 4 treatment-related adverse events occurred in 14% of patients, and there were 3 deaths from pulmonary toxicity. Similar to observations from the first-in-human trial, responses were durable: among 31 responding patients with 1 year or more of follow-up, 20 responses lasted 1 year or more. Data from this and trials of other agents blocking the PD-1 pathway (15–17) should inform future studies involving combinatorial immune-based approaches, which have shown preclinical evidence of synergistic antitumor activity (18, 19).

The colocalization of tumor-infiltrating T cells and PD-L1+ tumor and stromal cells seen in biopsies from the patients with CRC and melanoma reported here represents a more general phenomenon, and is consistent with observations suggesting that IFN- γ secretion by intratumoral lymphohistiocytic infiltrates fosters an immunosuppressive microenvironment by promoting PD-L1 expression ("adaptive immune resistance"; ref. 4). PD-1 pathway blockade may be particularly effective in these

cases, as illustrated by the recent report from Topalian and colleagues showing preliminary evidence for a correlation between tumor cell surface expression of PD-L1 in pretreatment tumor specimens and objective response to anti-PD-1 therapy (3). PD-L1 expression as a predictive tumor marker of response to reinduction therapy with PD-1 pathway blockade, as shown in the patient with melanoma described in this report, remains to be explored in larger studies.

Disclosure of Potential Conflicts of Interest

W.H. Sharfman has honoraria from speakers' bureau from Prometheus and is a consultant/advisory board member of Merck and Genentech. C.G. Drake is a consultant/advisory board member of Bristol Myers Squibb, Amplimmune Inc., and Dendreon Inc. R.A. Anders has a commercial research grant from BMS. S. Yao is employed (other than primary affiliation; e.g., consulting) in Amplimmune, Inc. as a scientist. D.M. Pardoll is a consultant/advisory board member of BMS. J.R. Brahmer is consultant/advisory board member of Bristol-Myers Squibb. S.L. Topalian has a commercial research grant from Bristol-Myers Squibb and is a consultant/advisory board member of Bristol-Myers Squibb and Amplimmune Inc. S.L. Topalian also has royalties via institution from Bristol-Myers Squibb and Amplimmune Inc. No potential conflicts of interest were disclosed by the other authors.

Authors' Contributions

Conception and design: E.J. Lipson, W.H. Sharfman, C.G. Drake, R.A. Anders, H. Xu, L. Chen, J.R. Brahmer, S.L. Topalian

Development of methodology: E.J. Lipson, J.M. Taube, R.A. Anders, H. Xu, S. Yao, L. Chen

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): E.J. Lipson, W.H. Sharfman, C.G. Drake, I. Wollner, J.M. Taube, A. Pons, J.R. Brahmer

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): E.J. Lipson, W.H. Sharfman, J.M. Taube, L. Chen, D.M. Pardoll, J.R. Brahmer, S.L. Topalian

Writing, review, and/or revision of the manuscript: E.J. Lipson, W.H. Sharfman, C.G. Drake, I. Wollner, J.M. Taube, H. Xu, S. Yao, L. Chen, D.M. Pardoll, J.R. Brahmer, S.L. Topalian

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): E.J. Lipson, H. Xu, A. Pons

Study supervision: E.J. Lipson, W.H. Sharfman, J.R. Brahmer, S.L. Topalian

Acknowledgments

The authors thank Marina Laiko for clinical research coordination and data management and Dr. Peter Burger for helpful discussions (Johns Hopkins University School of Medicine). The authors also thank Bristol-Myers Squibb for providing BMS-936558 for reinduction therapy.

Grant Support

This work was supported by the NIH (R01 CA142779; to J.M. Taube, L. Chen, D.M. Pardoll, and S.L. Topalian), the Melanoma Research Alliance (to J.M. Taube, L. Chen, D.M. Pardoll, and S.L. Topalian), the Laverna Hahn Charitable Trust (to E.J. Lipson, W.H. Sharfman, J.M. Taube, and S.L. Topalian), the Barney Family Foundation (to E.J. Lipson, W.H. Sharfman, J.M. Taube, and S.L. Topalian), the Commonwealth Foundation (to D.M. Pardoll), and the Seraph Foundation (to D.M. Pardoll).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received August 7, 2012; revised October 27, 2012; accepted November 3, 2012; published OnlineFirst November 20, 2012.

References

- Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1 (PD-L1) pathway to activate anti-tumor immunity. *Curr Opin Immunol* 2012;24:207-12.
- Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. *J Clin Oncol* 2010;28:3167-75.
- Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *N Engl J Med* 2012;366:2443-54.
- Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al. Co-localization of inflammatory response with B7-H1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. *Sci Transl Med* 2012;4:127ra37.
- Kamino H, Tam ST. Immunoperoxidase technique modified by counterstain with azure B as a diagnostic aid in evaluating heavily pigmented melanocytic neoplasms. *J Cutan Pathol* 1991;18:436-9.
- Kim PS, Ahmed R. Features of responding T cells in cancer and chronic infection. *Curr Opin Immunol* 2010;22:223-30.
- Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. *Proc Natl Acad Sci U S A* 2003;100:4712-7.
- Dunn GP, Old LJ, Schreiber RD. The three E's of cancer immunoediting. *Annu Rev Immunol* 2004;22:329-60.
- Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. *Sci Transl Med* 2011;3:75ra26.
- Weber J. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. *Oncologist* 2007;12:864-72.
- Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebba C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. *Clin Cancer Res* 2009;15:7412-20.
- Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med* 2010;363:711-23.
- Robert C, Thomas L, Bondarenko I, O'Day S, M DJW, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. *N Engl J Med* 2011;364:2517-26.
- Sharma P, Wagner K, Wolchok JD, Allison JP. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. *Nat Rev Cancer* 2011;11:805-12.
- Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. *N Engl J Med* 2012;366:2455-65.
- Patnaik A, Kang SP, Tolcher AW, Rasco DW, Papadopoulos KP, Beiram M, et al. Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors [abstract]. *J Clin Oncol* 2012;30 (suppl; abstr 2512).
- Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, Leiba M, et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. *Clin Cancer Res* 2008;14:3044-51.
- Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller A, Tsuji T, et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. *Proc Natl Acad Sci U S A* 2010;107:7875-80.
- Zhou Q, Munger ME, Veenstra RG, Weigel BJ, Hirashima M, Munn DH, et al. Coexpression of tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. *Blood* 2011;117:4501-10.